Crystalline forms of a Bruton's tyrosine kinase inhibitor Grant US-10961251-B1 United States of America 30 Mar 2021
Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor Grant US-10828259-B2 United States of America 10 Nov 2020
Crystalline forms of a brutons tyrosine kinase inhibitor Grant US-10752634-B2 United States of America 25 Aug 2020
Treatment method by combined use of MDM2 inhibitor and BTK inhibitor Application US-10485794-B2 United States of America 26 Nov 2019
Crystalline forms of a Bruton's tyrosine kinase inhibitor Grant US-10294231-B2 United States of America 21 May 2019
Crystalline forms of a Bruton's tyrosine kinase inhibitor Grant US-10294232-B2 United States of America 21 May 2019
Crystalline forms of a Bruton's tyrosine kinase inhibitor Grant US-10266540-B2 United States of America 23 Apr 2019
Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor Grant US-10213386-B2 United States of America 26 Feb 2019
Crystalline forms of a bruton's tyrosine kinase inhibitor Grant US-10125140-B1 United States of America 13 Nov 2018
Crystalline forms of a Bruton's tyrosine kinase inhibitor Grant US-10106548-B2 United States of America 23 Oct 2018
Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor Grant US-10010507-B1 United States of America 03 Jul 2018
Novel Formulations of a Bruton's Tyrosine Kinase Inhibitor Application US-20180028537-A1 United States of America 01 Feb 2018
Crystalline forms of a bruton's tyrosine kinase inhibitor Grant US-9828383-B1 United States of America 28 Nov 2017
Crystalline forms of a bruton's tyrosine kinase inhibitor Grant US-9725455-B1 United States of America 08 Aug 2017
Crystalline forms of a Bruton's tyrosine kinase inhibitor Grant US-9713617-B2 United States of America 25 Jul 2017
Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor Grant US-9655857-B2 United States of America 23 May 2017